|
|
| Cytomegalovirus (CMV) is a member of the herpesvirus family and is widely prevalent throughout the population. In the US around
50-80% of adults are infected by 40 years of age (US CDC figures) whereas in other parts of the world, especially developing
countries, prevalence is much higher even at younger ages. Usually CMV infections are dormant causing no significant health issues,
however, in certain populations with a weakened immune system e.g. HIV, transplants (HSCT) the virus can reactivate can cause
disease e.g. pneumonia. CMV infection is also a concern in the neonate after transmission from a pregnant women pre or post
partum. Approximately 1 in 150 children is born with a congenital CMV infection and 1 in 750 born with permanent disabilities due to
the virus. Vaccine manufacturers are currently pursuing both therapeutic (TX) and prophylatic (PX ) CMV vaccine approaches. The most advanced program is Sanofi Pasteur’s gB vaccine (+ MF59 adjuvant) where protective efficacy has been shown in post-partum women (Phase II). Other notable approaches are Vical’s VCL-CB01 DNA-based approach in HSCT seropositive recipient (Phase II). This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Cytomegalovirus vaccines (TX +PX approaches) across major Western and emerging markets to 2030. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon the level of populations targeted, which in turn are influenced by vaccine mechanism of action and vaccinee serostatus. Please Note: This product is delivered as a zip file |
Related Markets
Infectious Diseases Reports
- Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential
- Global Infectious Disease Treatment Market 2011-2014
- World Market for Anti-Infectives: Antifungals, Antibacterials and Antivirals (Treatments for HIV, HBV, HCV, Urinary Tract, Respiratory, Candidiasis and Other Infections)
- Global Infectious Disease Market Outlook: Facilities, Test Volume, and Sales Forecasts by Country
- Influenza Vaccine Market Opportunities and Challenges: Worldwide Forecast
